Curis Inc (CRIS) Stock Analysis

AI analysis of Curis Inc (CRIS)

Buy

Curis Inc appears to be a good buy right now due to its recent price surge of 75.19% over the last five days, indicating strong momentum. The RSI is at 80.385, suggesting it is in overbought territory but also reflects strong buying interest. The forward P/E ratio is currently at 0, which indicates potential for future earnings growth as the company progresses with its clinical trials. However, a significant risk is the net loss of $24.2 million reported for Q1 2026, which highlights ongoing financial challenges that could impact investor sentiment.

Analyst Ratings (4)

+1440.83% upside

Buy

4 Buy

0 Hold

0 Sell

Current: 0.71

Low

5.00

Average

11.00

High

17.00

H.C. Wainwright

Buy

$43

2026-07-24

H.C. Wainwright

2026-07-24

Price Target

$43

Buy

Evercore ISI

Outperform

$38

2026-01-05

Evercore ISI

2026-01-05

Price Target

$38

Outperform

Canaccord

Hold

$30

2025-12-22

Canaccord

2025-12-22

Price Target

$30

Hold

BofA

Buy

$35

2025-12-15

BofA

2025-12-15

Price Target

$35

Buy

Canaccord

Hold

$28

2025-12-02

Canaccord

2025-12-02

Price Target

$28

Hold

See All Ratings

Valuation Metrics

The current forward P/E ratio for Curis Inc (CRIS) is 0.00, compared to its 5-year average forward P/E of -1.88.

Forward P/E

Overvalued

5Y Average P/E

-1.88

Current P/E

0.00

Overvalued

-0.07

Undervalued

-3.69

Forward EV/EBITDA

Fair

5Y Average EV/EBITDA

-1.11

Current EV/EBITDA

0.04

Overvalued

0.34

Undervalued

-2.55

Forward P/S

Fair

5Y Average P/S

6.67

Current P/S

0.17

Overvalued

15.54

Undervalued

-2.20

Alphio AI Price Scenarios for CRIS

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%CRIS

$2.47

Scenario price

B

Base

Base · 50%CRIS

$2.05

Scenario price

B

Bear

Bear · 25%CRIS

$1.84

Scenario price

CRIS FAQ — answered by Alphio AI

Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). The Erivedge, is a commercialized orally administered small molecule Hedgehog signaling pathway antagonist. Its other clinical programs include Fimepinostat and CA-170. CA-170 is an oral small molecule drug candidate that targets V-domain Ig Suppressor of T-cell Activation, or VISTA, and PDL1 immune checkpoint proteins. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).

Curis Inc appears to be a good buy right now due to its recent price surge of 75.19% over the last five days, indicating strong momentum. The RSI is at 80.385, suggesting it is in overbought territory but also reflects strong buying interest. The forward P/E ratio is currently at 0, which indicates potential for future earnings growth as the company progresses with its clinical trials. However, a significant risk is the net loss of $24.2 million reported for Q1 2026, which highlights ongoing financial challenges that could impact investor sentiment.

4 analysts cover CRIS: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.